Integrated Filing — IndAS


General information about company

Scrip Code 543349
NSE Symbol AMIORG
MSEI Symbol NOTLISTED
ISIN INE00FF01025
Name of company AMI ORGANICS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 02-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others
Start date and time of board meeting 02-May-2025   11:30:00
End date and time of board meeting 02-May-2025   12:55:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-04-12
Indicate Company website link for updated RPT policy of the Company https://www.amiorganics.com/static/uploadfiles/downloads/download_4637.pdf?20240413045446
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not applicable, no default.



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3041614000 9898346000
Other income 56942000 183356000
Total income 3098556000 10081702000
2 Expenses
(a) Cost of materials consumed 1632140000 5668402000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -19787000 -186456000
(d) Employee benefit expense 226100000 809472000
(e) Finance costs 3833000 58574000
(f) Depreciation, depletion and amortisation expense 65565000 240452000
(f) Other Expenses
1 Other Expenses 362586000 1355505000
Total other expenses 362586000 1355505000
Total expenses 2270437000 7945949000
3 Total profit before exceptional items and tax 828119000 2135753000
4 Exceptional items 0 0
5 Total profit before tax 828119000 2135753000
6 Tax expense
7 Current tax 152294000 469708000
8 Deferred tax 47357000 70583000
9 Total tax expenses 199651000 540291000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 628468000 1595462000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 628468000 1595462000
17 Other comprehensive income net of taxes 3511000 -1092000
18 Total Comprehensive Income for the period 631979000 1594370000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 409345000 409345000
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve 12706607000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.84 19.91
Diluted earnings (loss) per share from continuing operations 7.84 19.91
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.84 19.91
Diluted earnings (loss) per share from continuing and discontinued operations 7.84 19.91
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 4959137000
Capital work-in-progress 1302841000
Investment property 0
Goodwill 0
Other intangible assets 33150000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 697979000
Trade receivables, non-current 0
Loans, non-current 33036000
Other non-current financial assets 123559000
Total non-current financial assets 854574000
Deferred tax assets (net) 0
Other non-current assets 516712000
Total non-current assets 7666414000
2 Current assets
Inventories 1740012000
Current financial asset
Current investments 0
Trade receivables, current 2892119000
Cash and cash equivalents 1846070000
Bank balance other than cash and cash equivalents 561176000
Loans, current 21458000
Other current financial assets 652298000
Total current financial assets 5973121000
Current tax assets (net) 0
Other current assets 0
Total current assets 7713133000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 15379547000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 409345000
Other equity 12706607000
Total equity attributable to owners of parent 13115952000
Non controlling interest
Total equity 13115952000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 47544000
Total non-current financial liabilities 47544000
Provisions, non-current 22065000
Deferred tax liabilities (net) 203591000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 273200000
Current liabilities
Current financial liabilities
Borrowings, current 63490000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 543227000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1012137000
Total Trade payable 1555364000
Other current financial liabilities 0
Total current financial liabilities 1618854000
Other current liabilities 130551000
Provisions, current 240811000
Current tax liabilities (Net) 179000
Deferred government grants, Current 0
Total current liabilities 1990395000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 2263595000
Total equity and liabilites 15379547000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Unaudited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined employee benefit plans 4692000 -1459000
Total Amount of items that will not be reclassified to profit and loss 4692000 -1459000
2 Income tax relating to items that will not be reclassified to profit or loss 1181000 -367000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 3511000 -1092000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2135753000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 58574000
Adjustments for decrease (increase) in inventories -228114000
Adjustments for decrease (increase) in trade receivables, current -725854000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 51519000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current -110312000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 222489000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -21529000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 240452000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 126448000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -59350000
Adjustments for dividend income 4000
Adjustments for interest income 102950000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 29987000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships -20669000
Total adjustments for reconcile profit (loss) -539313000
Net cash flows from (used in) operations 1596440000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 437161000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 1159279000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 1910060000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 4000
Interest received 102950000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -536615000
Net cash flows from (used in) investing activities -2343721000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 4993888000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 1963807000
Payments of lease liabilities 3364000
Dividends paid 122783000
Interest paid 58369000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -109936000
Net cash flows from (used in) financing activities 2735629000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1551187000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 1551187000
Cash and cash equivalents cash flow statement at beginning of period 294883000
Cash and cash equivalents cash flow statement at end of period 1846070000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s. Maheshwari & Co. Yes 28-Feb-2026


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 31-May-2024
Amount Raised 990999000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NIL
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Capital Expenditure required for electrolytes additives and /or allied business of the Company and/or its subsidiaries NOT APPLICABLE 770000000 0 455122000 0
2 GENERAL CORPORATE PURPOSE NOT APPLICABLE 220999000 0 220999000 0


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 21-Jun-2024
Amount Raised 3884300000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE RATING LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NIL
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment/ pre-payment, in part or full, of certain outstanding borrowings availed by the Company NOT APPLICABLE 2500000000 0 2500000000 0
2 Funding of various capex of Company including towards establishment of captive solar power projects NOT APPLICABLE 500000000 0 500000000 0
3 General Corporate Purpose NOT APPLICABLE 884300000 0 884300000 0


Signatory Details

Name of signatory EKTA KUMARI SRIVASTAVA
Designation of person Company Secretary and Compliance Officer
Place SURAT
Date 02-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Ami Organics Limited Nareshkumar R. Patel Managing Director (KMP) Remuneration Not Applicable 24600000 0 0
2 Ami Organics Limited Chetankumar C. Vaghasia Whole Time Director (KMP) Remuneration Not Applicable 24258000 0 0
3 Ami Organics Limited Virendra Nath Mishra Whole Time Director (KMP) Remuneration Not Applicable 6609000 0 0
4 Ami Organics Limited Ram Mohan Lokhande Whole Time Director (KMP) Remuneration Not Applicable 6086000 0 0
5 Ami Organics Limited Hetal M. Gandhi Independent Director Any other transaction Director Sitting Fees Not Applicable 270000 0 0
6 Ami Organics Limited Hetal M. Gandhi Independent Director Any other transaction Commission Not Applicable 1310000 0 1310000
7 Ami Organics Limited Girikrishna Maniar Independent Director Any other transaction Director Sitting Fees Not Applicable 270000 0 0
8 Ami Organics Limited Girikrishna Maniar Independent Director Any other transaction Commission Not Applicable 1190000 0 1190000
9 Ami Organics Limited Richa M. Goyal Independent Director Any other transaction Director Sitting Fees Not Applicable 360000 0 0
10 Ami Organics Limited Richa M. Goyal Independent Director Any other transaction Commission Not Applicable 310000 0 310000
11 Ami Organics Limited Anita Bandyopadhyay Independent Director Any other transaction Director Sitting Fees Not Applicable 150000 0 0
12 Ami Organics Limited Anita Bandyopadhyay Independent Director Any other transaction Commission Not Applicable 640000 0 640000
13 Ami Organics Limited Bhavin N. Shah Chief Financial Officer Remuneration Not Applicable 3879000 0 0
14 Ami Organics Limited Ekta Kumari Company Secretary Remuneration Not Applicable 863000 0 0
15 Ami Organics Limited Ami Organics Electrolytes Private Limited Wholly Owned Subsidiary Loan 100000000 As per Omnibus Approval 500000 2952000 3002000 Loan 0.08 12 months Unsecured Working Capital
16 Ami Organics Limited Ami Organics Electrolytes Private Limited Wholly Owned Subsidiary Interest received 100000000 As per Omnibus Approval 1283000 1833000 3011000
17 Ami Organics Limited Ami Organics Electrolytes Private Limited Wholly Owned Subsidiary Any other transaction Rent Receivable 100000000 As per Omnibus Approval 60000 120000 180000
18 Ami Organics Limited Ami Organics Electrolytes Private Limited Wholly Owned Subsidiary Any other transaction Reimbursement Receivable 100000000 As per Omnibus Approval 1787000 9770000 11551000
19 Ami Organics Limited Baba Advance Materials Limiteed Wholly Owned Subsidiary Any other transaction Rent Receivable 100000000 As per Omnibus Approval 60000 120000 30000
20 Ami Organics Limited Baba Advance Materials Limiteed Wholly Owned Subsidiary Any other transaction Loan Repayment 100000000 As per Omnibus Approval 800000 800000 0
21 Ami Organics Limited Baba Advance Materials Limiteed Wholly Owned Subsidiary Interest received 100000000 As per Omnibus Approval 22000 197000 0
22 Ami Organics Limited Baba Advance Materials Limiteed Wholly Owned Subsidiary Any other transaction Reimbursement Receivable 100000000 As per Omnibus Approval 1217000 1069000 22000
23 Ami Organics Limited Baba Fine Chemicals Subsidiary Sale of goods or services 100000000 As per Omnibus Approval 2048000 0 102000
24 Ami Organics Limited Baba Fine Chemicals Subsidiary Purchase of goods or services 100000000 As per Omnibus Approval 25000 0 30000
25 Ami Organics Limited Alkoxide Fine Chem Private Limited A private company in which a director's relative is a member or director Purchase of goods or services 50000000 As per Omnibus Approval 6215000 2798000 3093000
26 Ami Organics Limited Avinash Kumar Relative of KMP Remuneration Not Applicable 409000 0 0
27 Ami Organics Limited Globe Biocare Firm in which Director is Partner Any other transaction Rent Payable 50000000 As per Omnibus Approval 0 2310000 2310000
Total value of transaction during the reporting period 85221000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt